From: Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective
BCVA level
BSE utility
WSE utility
86–100
0.85
76–85
0.76
0.84
66–75
0.69
0.82
56–65
0.61
0.81
46–55
0.54
0.79
36–45
0.46
0.78
26–35
0.39
0.75
< 25
0.35